AWM
AMLX icon

Aries Wealth Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Aries Wealth Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,000
Closed -$48.6K – 226
2024
Q3 		$48.6K Buy
+15,000
New +$33.7K 0.01% 226

Other funds holding AMLX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Aries Wealth Management's AMLX Position: Q4 2024 in Review

Aries Wealth Management sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2024, closing a stake of 15,000 shares — an estimated $48.6K sold.

Aries Wealth Management first reported a position in AMLX in Q3 2024 and held it in 1 quarter. The position peaked at $48.6K in Q3 2024. 122 funds tracked by Wall St. Rank hold AMLX as of Q4 2024.

  • Aries Wealth Management reported no remaining Amylyx Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Aries Wealth Management sold 15,000 Amylyx Pharmaceuticals shares in Q4 2024, an estimated $48.6K.
  • Aries Wealth Management first reported a position in Amylyx Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Aries Wealth Management's Amylyx Pharmaceuticals position peaked at $48.6K in Q3 2024.
  • 122 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2024.

Based on Aries Wealth Management's 13F filing for Q4 2024, filed 30 Jan 2025.